gdc
PoetrySkin Cancer

May is Skin Cancer Awareness Month

A poem by Tonya Marie Pan, MA, MS.
June 2016 Vol 2 No 3
Tonya Marie Pan, MA, MS
Graduate Student, San Diego Joint Doctoral Program in Clinical Psychology San Diego State University/University of California

I’m guilty. I’ve thought it: “It’s only skin cancer.”
I’m guilty. I’ve thought it: “That’s one of the easy cancers.”
I’m guilty. I’ve thought it: “You didn’t lose your hair or go through chemo; you’re not a real cancer survivor.”

Tell that to the man who just walked into my office with the scars on his head and a broken back from removing the metastases of his “easy cancer.”

Tell that to the man who has yet to experience middle age and likely won’t see his kids graduate from college.
Tell that to the man with hints of orbitofrontal syndrome and enough awareness to know that he’s losing himself.
Tell that to the man who thinks his recurrence is his fault.
Tell that to the man, because I can’t.

Acknowledgment

Many thanks to Bradley M. Weisz, MA, for his enduring support and helpful edits.

Share this:

Recommended For You
ImmunotherapyPatient StoriesSkin Cancer
Is It Breast or Skin Cancer? How a Misdiagnosis Shaped My Cancer Journey
By Chris Andersen
Chris Andersen learned the value of trusting one’s instincts and asking for a second opinion after receiving a misdiagnosis of breast cancer that was later diagnosed as metastatic skin cancer and she was told she had 1 to 2 years to live. Thanks to a new treatment for skin cancer, she now has no signs of cancer.
Skin Cancer
Libtayo Extends Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
By Chase Doyle
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
ImmunotherapySkin Cancer
Libtayo Reduces Pain, Improves Quality of Life in Patients with Advanced Cutaneous Squamous-Cell Carcinoma
By Chase Doyle
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
ImmunotherapySkin Cancer
Immunotherapy with Libtayo Prolongs Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
By Chase Doyle
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC.
Last modified: March 27, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country